CompoAtlas

ASPRIVA - GLOW (myrtille-framboise)

Food supplement declared in France, decision dated 9 September 2025

ASPRIVA - GLOW (myrtille-framboise) is a food supplement declared in France. Status: déclaré en France, commercialisation possible : l'administration ne s'est pas opposée à la déclaration (ce n'est ni une autorisation ni une évaluation de sécurité). None of the rules we check flags an issue with its declared composition; vitamin and mineral doses are not published by Compl'Alim and are therefore not checked.

Brand
not provided
Food business operator placing the product on the market
ASPRIVA GmbH
Status
Déclaré en France, commercialisation possible : l'administration ne s'est pas opposée à la déclaration (ce n'est ni une autorisation ni une évaluation de sécurité)
Form
Sachet
Daily dose
1 sachet (10 g) par jour
Intended populations
Hommes et femmes de 18 ans et plus
Not recommended for (according to the manufacturer)
Adolescents (moins de 18 ans), Femmes allaitantes, Autre : N/A, Femmes enceintes, Sous antidépresseurs
Objectives stated by the manufacturer (these are not authorised claims)
Autre : N/A
Flavourings
myrtille-framboise

Declaration 339768, procedure Article 15. Compl'Alim, food supplement declarations (France), retrieved 23 October 2026.

Regulatory points

None of the rules we check applies to the declared ingredients.

Declared composition

Plants

PlantPartPreparationPer day
Vaccinium uliginosum L.FruitExtrait sec hydroalcoolique400 mg
Haematococcus pluvialis FlotowPlante entièreExtrait sec hydroalcoolique300 mg
Pinus sylvestris L.EcorceExtrait sec hydroalcoolique1 mg

Substances

NamePer day
lycopène15 mg

Other active ingredients

NamePer day
Ubiquinonenot declared
Hyaluronate de sodiumnot declared
Collagène hydrolysénot declared

Vitamins and minerals

Compl'Alim does not publish vitamin and mineral doses. The references below help you read the product label: EFSAEuropean Food Safety Authority. safety limit for adults and maximum dose set in France per product (Order of 9 May 2006, not revised since November 2006).

Declared formNutrientEFSA limit, adults Maximum dose in France
Sélénite de sodiumSélénium255 µg50 µg
Acétate de DL-alpha-tocophéryleVitamine E300 mg30 mg
Bisglycinate de zincZinc25 mg15 mg

Additives

E960

Other ingredients

Vaccinium myrtillus L., Jus d'acérola

List from the declaration, administrative decision dated (Compl'Alim, food supplement declarations (France)).

Has the product changed? Photograph the packaging.

Label warnings

Ne pas dépasser la dose journalière recommandée. Les compléments alimentaires ne doivent pas se substituer à une alimentation variée et équilibrée et à un mode de vie sain. Ne pas laisser à la portée des jeunes enfants. Déconseillé aux femmes enceintes ou allaitantes. Reserve a l’adulte. À ne pas consommer le même jour si d’autres compléments alimentaires contenant des esters d’astaxanthine sont consommés le même jour.

This information reproduces the manufacturer's declaration to the administration (DGAL). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.

Official warnings (Health Canada)

Health Canada publishes warnings on these ingredients:

  • Haematococcus pluvialis Flotow
    Read the warning, when it applies and the studies cited

    Haematococcus pluvialis extract

    Route of administration: Oral

    Cautions and warnings

    Condition of application: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.

    Condition of application: Eye strain, Eye fatigue.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Health Canada monograph dated 10 January 2025

  • Ubiquinone
    Read the warning, when it applies and the studies cited

    Coenzyme Q10 (UBIQUINONE-10)

    Route of administration: Oral

    Cautions and warnings

    Condition of application: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood pressure medication (Rosenfeldt et al. 2007; Singh et al. 1999).

    2 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Applies to products providing more than 100 mg of Coenzyme Q10 per day.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood thinners (Engelsen et al. 2003; Landbo and Almdal 1998; Spigset 1994).

    3 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Condition of application: Migraine prophylaxis/prevention.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if migraine frequency increases and associated nausea and vomiting persist or worsen.

    Health Canada monograph dated 31 January 2025

  • Collagène hydrolysé
    Read the warning, when it applies and the studies cited

    Hydrolyzed Collagen

    Route of administration: Oral

    Cautions and warnings

    Condition of application: Joint pain.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms worsen.

    Applies to products providing more than 2.8 g hydrolyzed collagen, per day.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (Shils et al. 2006; Goldman and Ausiello 2004).

    2 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Known adverse reactions

    When using this product you may experience gastrointestinal discomfort/disturbances (Moskowitz 2000).

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    Health Canada monograph dated 28 March 2024

They concern the ingredient, not this product or its dose. They do not replace medical advice.

Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.

Enter to analyse, Shift+Enter for a new line